Takeda’s EXKIVITY^® (Mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Takeda announced that EXKIVITY® (mobocertinib) was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) Exon20 insertion mutations, whose disease had progressed on or after platinum-based chemotherapy.